| 生物活性 |
Azaleatin is an orally active inhibitor of hQC, NS2B-NS3 protease, and Escherichia coli β-glucuronidase with IC50 values of 1.1 μM, 38.00 μg/mL, and 0.57 μM, respectively; it inhibits the activities of NF-κB, MyD88, JAK1, TLR4, STAT3, IL-1β, IL-6, COX-2, TNF-α, and β-glucuronidase to block pro-inflammatory signaling pathways, reduces ROS, MDA, and uric acid levels, elevates GPx, GSR, GST, SOD, CAT, HO-1, and GSH levels, scavenges free radicals, and exerts reducing capacity, while also inhibiting the expression of pro-apoptotic proteins Bax, Caspase-9, and Caspase-3 and upregulating the expression of the anti-apoptotic protein Bcl-2; furthermore, it reduces cardiac injury marker levels, restores cardiac histological structure, inhibits Aβ aggregation, dengue protease activity, hepatic stellate cell proliferation, and cancer cell growth, and possesses antibacterial activity, making it applicable for research on subchronic cardiotoxicity, Alzheimer's disease, dengue fever, hyperuricemia, liver fibrosis, gastric cancer, and bacterial infections. |
| IC50 & Target |
|
|
|
DPP-4
|
JAK1
|
TLR4
|
STAT3
|
IL-6
|
IL-1β
|
|
|
COX-2
|
hQC
1.1 μM (IC50)
|
hQC
0.4 nM (Kd)
|
GSR
|
GST
|
Caspase-9
|
|
|
Caspase-3
|
|
体外研究 (In Vitro) |
Azaleatin 可与 NF-κB、TLR4 和 STAT3 蛋白强烈结合,其中对 NF-κB 的亲和力最高 (-8.5 kcal/mol),表明其具有调控促炎信号通路的潜力。 Azaleatin (多浓度;5 min) 在生化实验中可强效抑制人谷氨酰胺环化酶 (hQC),其 IC50 为 1.1 μM。 Azaleatin (12.5-100 μM) 以高亲和力结合纯化的人谷氨酰胺酰环化酶 (hQC),通过表面等离子体共振测得其 KD 为 0.4 nM。 Azaleatin 可通过与催化锌离子配位、形成氢键、阴离子-π 相互作用及与关键残基的疏水相互作用,结合人谷氨酰胺酰环化酶 (hQC) 的活性位点,以此支持其抑制活性。 Azaleatin 符合 Lipinski 五规则,且具有良好的药代动力学特征,包括吸收性好、无致癌性,与槲皮素相比生物利用度更高。 Azaleatin 结合于 β-葡萄糖醛酸苷酶的中央活性位点 (PDB ID: 3K4D),结合亲和力为-8.5 kcal/mol,可与关键酶残基形成极性和疏水相互作用。 Azaleatin 与 β-葡萄糖醛酸苷酶 (PDB ID: 3K4D) 在 50 ns MD 模拟过程中形成稳定复合物,表现出强静电相互作用、稳固的氢键结合以及酶柔性降低的特征,与其高效的体外抑制活性一致。 Azaleatin (10-30 μM; 2 h) 在 AML12 肝细胞中呈浓度依赖性抑制尿酸生成。Azaleatin (5-80 μM; 6-24 h) 可在孵育 24 h 后以 80 μM 浓度抑制大鼠肝星状细胞 (HSC-T6) 的增殖;在 6 h 时观察到其呈剂量依赖性促进细胞增殖,而在 12 h 以内的低剂量下无作用。 Azaleatin (20-40 μM; 24 h) 可呈剂量依赖性降低 αSMA 的累积,并在 20 μM 和 40 μM 浓度下共处理 24 小时后,有效抑制 TGFβ 诱导的大鼠肝星状细胞 (HSC-T6) 中 I 型胶原蛋白的生成。 Azaleatin (20 μM; 1-6 h) 不抑制 TGFβ 诱导的 αSMA 或 Timp1 mRNA 表达,但在 20 μM 浓度下共处理 6 小时后,可在 TGFβ 诱导的大鼠肝星状细胞 (HSC-T6) 中以时间依赖的方式降低 I 型胶原 mRNA 表达。 Azaleatin (5-1,000 μg/mL) 可通过清除 DPPH、超氧阴离子及羟自由基,同时借助还原能力在体外展现抗氧化活性,但无金属螯合活性,其 EC50 值分别为 37 μg/mL (DPPH)、90 μg/mL (超氧阴离子)、688 μg/mL (羟自由基) 及 27 μg/mL (还原能力)。 Azaleatin 存在于烈香杜鹃的乙醇提取物中,经 UPLC定量分析其含量为 0.10 mg/g 鲜重材料。 Azaleatin (5 mg) 以其 3-O-α-L-鼠李糖苷衍生物 (杜鹃花素) 的形式存在于 Azara dentata 的乙醇果实提取物中,该物质通过 UHPLC-ESI-Q-TOF-MS 鉴定,其假分子离子质荷比为 m/z: 461.1064,对应杜鹃花素的子离子质荷比为 m/z: 287.0555。 Azaleatin (3.125-200 μg/mL; 20-100 μg/mL) 非竞争性抑制登革热 NS2B-NS3 血清型 2 蛋白酶,其 IC50 为 38 μg/mL,Ki 为 26.82 μg/mL。 Azaleatin 结合登革热 NS2B-NS3 蛋白酶的变构口袋 (PDB ID: 3U1I),对接分数为 -8.2 kcal/mol,可与关键功能残基形成氢键和疏水相互作用。 Azaleatin (100 ns) 与登革热 NS2B-NS3 蛋白酶 (PDB ID: 3U1I) 在 100 ns 的模拟过程中形成稳定复合物,可稳定该酶的闭合构象并支持其非竞争性抑制模式。 Azaleatin (0.001-1000 μM; 30 min) 可通过非竞争性机制强效抑制大肠杆菌 β-葡萄糖醛酸苷酶,其 IC50 为 0.57 μM,Ki 为 0.66 μM。 Azaleatin (10-250 μM; 48 h) 可抑制 HGC-27 细胞的活力,其显著的生长抑制作用从 10 μM 开始显现,在最高测试浓度下细胞活力降至对照组的约 40%,且在所测试的三种黄酮类化合物中,它是抑制细胞生长效果最弱的一种。 Azaleatin (20-35 μM; 24 h) 可在 20 μM 及更高浓度、孵育 24 小时后显著提高 HGC-27 细胞中的戊糖苷水平,其效力中等,高于山柰酚但低于杨梅素。 Azaleatin (15-35 μM; 24 h) 在 HGC-27 细胞中诱导 3-脱氧葡萄糖酮水平呈剂量依赖性升高,从 15 μM 开始出现显著升高,在最高测试浓度下达到对照组水平的 2.5 倍,且在所测试的黄酮类化合物中,它在该指标上的效果最弱。 Azaleatin (5-35 μM; 24 h) 可强效升高 HGC-27 细胞中的甲基乙二醛水平,起始作用浓度为 5 μM,在最高测试浓度下其水平可达对照组的约 3.3 倍,就该指标而言,它的效果远优于其他受试黄酮类化合物。
Cell Proliferation Assay
| Cell Line: |
HSC-T6 (rat hepatic stellate cells) |
| Concentration: |
5, 10, 20, 40 and 80 μM |
| Incubation Time: |
6, 12 and 24 h |
| Result: |
Increased HSC-T6 proliferation in a dose-dependent manner after 6 h treatment. Decreased proliferation to levels comparable to non-treated controls after 12 h treatment. Markedly suppressed HSC-T6 proliferation at 80 μM after 24 h incubation; no inhibitory effect was observed at lower doses (5, 10, 20, 40 μM) up to 12 h. |
Immunofluorescence
| Cell Line: |
HSC-T6 (TGFβ-induced rat hepatic stellate cells) |
| Concentration: |
20 and 40 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced αSMA accumulation compared to TGFβ-induced positive controls, with dose-dependent enhancement from 20 μM to 40 μM; the inhibitory effect was weaker than other methylated quercetin derivatives. Effectively inhibited collagen I production in TGFβ-induced HSC-T6 cells. |
Real Time qPCR
| Cell Line: |
HSC-T6 (TGFβ-induced rat hepatic stellate cells) |
| Concentration: |
20 μM |
| Incubation Time: |
1 and 6 h |
| Result: |
Did not inhibit TGFβ-induced augmentation of αSMA mRNA after 1 h co-treatment. Decreased αSMA mRNA levels after 6 h co-treatment, though levels remained higher than non-treated controls. Increased collagen I mRNA after 1 h co-treatment but decreased it after 6 h in a time-dependent manner. Did not inhibit TGFβ-induced increases in Timp1 mRNA expression after 6 h co-treatment. |
Cell Viability Assay
| Cell Line: |
HGC-27 immortalised human-stomach adenocarcinoma cells |
| Concentration: |
0, 50, 100, 150, 200 and 250 μM |
| Incubation Time: |
48 h |
| Result: |
Significantly inhibited HGC-27 cell growth starting at 10 μM. Reduced cell viability to approximately 40% of control at the highest tested concentration. Ranked as the least effective cell growth inhibitor among kaempferol, myricetin, and azaleatin. |
Cell Viability Assay
| Cell Line: |
AML12 cells |
| Concentration: |
0, 3, 10 and 30 μM |
| Incubation Time: |
2 h |
| Result: |
Significantly and dose-dependently decreased the uric acid production in the hepatocytes. At dose of 3 μM did not inhibit uric acid production. At 10 μM significantly suppressed uric acid production. At 30 μM significantly suppressed uric acid production. Showed more notable inhibitory effect at 30 μM than that at lower concentrations. |
|
体内研究 (In Vivo) |
Azaleatin (25 mg/kg;口服;8 周) 可通过恢复氧化还原平衡、抑制促炎基因表达、降低心肌损伤标志物水平、调控凋亡通路及维持心肌组织形态,对亚慢性亚砷酸钠诱导的雄性 Sprague Dawley 大鼠心肌损伤发挥保护作用。 Azaleatin (25 mg/kg;口服;8 周) 在健康雄性 Sprague Dawley 大鼠中耐受性良好,且不会诱发心脏不良反应。
| Animal Model: |
Male Sprague-Dawley rats (13-14 weeks old, 225 g) were orally administered sodium arsenite (10 mg/kg) for 8 weeks to induce myocardial injury. Meanwhile, the compound was orally administered to evaluate its cardioprotective effects.
|
| Dosage: |
25 mg/kg |
| Administration: |
p.o.; daily; 8 weeks |
| Result: |
Significantly downregulated mRNA expressions of pro-inflammatory genes (NF-κB, MyD88, JAK1, TLR4, STAT3, IL-6, IL-1β, TNF-α) to levels not significantly different from the control group. Restored cardiac antioxidant enzyme activities: catalase (CAT) increased from 2.27 U/mg protein to 8.50 U/mg protein; superoxide dismutase (SOD) increased from 2.02 U/mg protein to 5.47 U/mg protein; glutathione reductase (GSR) increased from 2.48 nM NADPH oxidized/min/mg tissue to 5.24 nM NADPH oxidized/min/mg tissue; glutathione peroxidase (GPx) increased from 3.49 U/mg protein to 11.81 U/mg protein; glutathione (GSH) increased from 3.06 μmol/g tissue to 9.37 μmol/g tissue; glutathione S-transferase (GST) increased from 4.28 U/mg protein to 14.92 U/mg protein; heme-oxygenase-1 (HO-1) increased from 68.58 pmoles bilirubin/mg protein/h to 231.18 pmoles bilirubin/mg protein/h. Reduced oxidative stress markers: malondialdehyde (MDA) decreased from 13.61 nmol/g to 5.09 nmol/g; reactive oxygen species (ROS) decreased from 13.28 nmol/g to 4.47 nmol/g. Reduced cardiac injury marker levels: CK-MB decreased from 83.05 ng/mL to 47.02 ng/mL; CPK decreased from 491.67 mcg/L to 273.89 mcg/L; troponin-I decreased from 5.89 pg/mL to 2.33 pg/mL; troponin-T decreased from 3.67 ng/mL to 1.59 ng/mL; LDH decreased from 42.10 mg/mL to 20.63 mg/mL; BNP decreased from 78.75 pg/mL to 40.89 pg/mL; NT-proBNP decreased from 316.73 pg/mL to 178.14 pg/mL; CRP decreased from 19.38 mg/L to 10.91 mg/L. Modulated apoptotic markers: Bax decreased from 15.15 pg/mL to 4.97 pg/mL; caspase-9 decreased from 14.19 pg/mL to 6.46 pg/mL; caspase-3 decreased from 12.81 pg/mL to 3.43 pg/mL; Bcl-2 increased from 3.84 ng/mL to 8.34 ng/mL. Prevented sodium arsenite-induced cardiac damage (myofiber degeneration, hypertrophy, vascular congestion, edema, hemorrhage, inflammation, dysregulated intercalated discs), preserving near-normal cardiac architecture. Showed values for all measured parameters comparable to the control group in the azaleatin-only group, indicating a safe profile at the tested dose. |
| Animal Model: |
Sprague Dawley (male, 13-14 weeks old, 225 g) |
| Dosage: |
25 mg/kg |
| Administration: |
p.o.; 8 weeks |
| Result: |
Resulted in mRNA expressions of pro-inflammatory genes (NF-κB, MyD88, JAK1, TLR4, STAT3, IL-6, IL-1β, TNF-α), antioxidant enzyme activities, oxidative stress marker levels, cardiac injury marker levels, apoptotic marker levels, and cardiac histology that were all comparable to the control group, with no significant differences detected. |
|
| 性状 |
固体 |
| 颜色 |
Off-white to light yellow |